Investment21 Aug 2025, 05:01 pm
Piramal Pharma Solutions Invests in Dedicated Oral Solid Dosage Suite for NewAmsterdam Pharma
AI Summary
Piramal Pharma Solutions (PPS) and NewAmsterdam Pharma have invested in a dedicated oral solid dosage (OSD) form suite at PPS's Sellersville, Pennsylvania site. This multi-million-dollar investment will enhance PPS's OSD capabilities and provide NewAmsterdam Pharma with commercial capacity for its fixed dose combination (FDC) of obicetrapib and ezetimibe. The partnership between the two companies extends beyond the Sellersville site, with PPS's Ahmedabad and Pithampur sites in India playing crucial roles in the product's development and dual sourcing support.
Key Highlights
- Piramal Pharma Solutions and NewAmsterdam Pharma invest in a dedicated OSD suite at PPS's Sellersville, Pennsylvania site.
- The investment is a multi-million-dollar commitment to enhance PPS's OSD capabilities and meet potentially high commercial demand for NewAmsterdam Pharma's FDC of obicetrapib and ezetimibe.
- PPS's integrated approach to development is demonstrated through the involvement of two additional facilities in the production of the FDC.
- The new suite is designed for turnkey, multi-layer tablet production, equipped with advanced capabilities and technology to support granulation, compression, tableting, and coating.
- The investment is expected to create more than 20 new jobs at the Sellersville site over the next five years.